GLP1R and metabolic dysfunction-associated steatotic liver disease: Glucagon-like peptide-1 receptor agonist (GLP-1R) liraglutide, an antidiabetic agent for T2DM patients, reportedly exerts beneficial effects in NAFLD [10–12], with the underlying mechanisms potentially involving body weight reduction, improved blood glucose regulation, decreased lipid synthesis, autophagy induction, and free fatty acid β-oxidation [10, 13].